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function of primitive hematopoietic cells 
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Abstract 
Background: In clinic settings, relapsed leukemic patients are found to be more fragile to chemotherapy due to 
delayed or incomplete hematopoietic recovery, and hematopoiesis of these patients seem to be impaired.
Methods: We established a leukemia therapy model with a non-irradiated T cell acute lymphoblastic leukemia 
mouse model combined with cytarabine and cyclophosphamide. Dynamic kinetics and functional status of both 
primitive hematopoietic cells and leukemic cells in a leukemia host under the chemotherapy stress were comprehen-
sively investigated.
Results: We successfully established the leukemia therapy model with T lymphoblastic phenotype. After treatment 
with cytarabine and cyclophosphamide, the frequency of L−K+S+ hematopoietic cells tides with the therapy, and sta-
bled when the disease remission, then reduced when relapsed, while leukemic cells showed a delayed but consistent 
regeneration. Combination of chemotherapy significantly promote an early and transient entrance of L−K+S+ hemat-
opoietic cells into active proliferation and induction of apoptosis on L−K+S+ cells in vivo. Moreover, in the competitive 
bone marrow transplantation assays, hematopoietic cells showed gradually diminished regenerative capacity. Testing 
of senescence-associated beta-galactosidase (SA-β gal) status showed higher levels in L−K+S+ hematopoietic cells 
post therapy when compared with the control. Gene expression analysis of hematopoietic primitive cells revealed up-
regulated p16, p21, and down-regulated egr1 and fos.
Conclusion: We conclude that primitive hematopoietic cells in bone marrow enter proliferation earlier than leuke-
mic cells after chemotherapy, and gradually lost their regenerative capacity partly by senescence due to accelerated 
cycling.
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Background
Leukemia is the most common hematopoietic malig-
nancy, characterized by uncontrollable growth of 
leukemic cells and gradual exhaustion of normal hemat-
opoiesis. It is well known that hematopoiesis is a hier-
archical system, with primitive hematopoietic cells as 
ancestors, usually named as hematopoietic stem/progen-
itor cells (HSPCs). Previously we have revealed kinetics 
of these cells in an irradiated acute T cell lymphoblastic 
leukemia (T-ALL) mice model [1]. We found that primi-
tive hematopoietic cells preserved their regenerative 
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capacity in a quiescent cell cycle state even when the 
numbers decreased. The fate of these cells was more 
likely depended on the changes of micro-environment 
rather than cells themselves. In fact, in early 2008, 
researchers found that leukemic cells could create a spe-
cial environment that affected maintenance of primitive 
hematopoietic cells [2].
In the past few decades, chemotherapy has remained 
to be the primary treating strategy for most leukemic 
patients. The rate of complete remission (CR), achieved 
by modern intensive chemotherapy, is 80–90% in adult 
patients with acute lymphoblastic leukemia. However, 
the relapse rate is more than 60% [3]. For these relapsed 
cases, treatment choices are limited, partially due to drug 
resistance and decreased tolerance to further chemother-
apy [4]. Moreover, hematopoiesis of these patients has 
also been impaired. Considering the findings of normal 
hematopoiesis in leukemic hosts mentioned above, we 
propose that the chemotherapy has impaired hematopoi-
etic regenerative capacity in leukemic patients.
However, quantitative, especially functional changes 
of primitive hematopoietic and leukemic cells post 
chemotherapy have not been well clarified yet. In the 
present study, kinetics of both hematopoietic primitive 
cells and leukemia cells and functional status of L−K+S+ 
hematopoietic cells in bone marrow in a treated leuke-
mic mouse model were investigated. In addition, SA-β 
gal status and gene expression such as p16 and EGR1 of 
bone marrow L−K+S+ hematopoietic cells were tested to 
obtain more insight in underlying the mechanism. Our 
data indicated that bone marrow primitive hematopoietic 
cells regenerated earlier than leukemic cells in a leukemia 
therapy model, and their repopulating capacity gradu-
ally diminished after treatment partly due to senescence 
caused by accelerated cycling.
Methods
Chemotherapeutic agents
Chemotherapeutic agents were Cyclophosphamide 
(CTX, Jiangsu Hengrui Medicine, CO., LTD) and Cytara-
bine (Ara-C, Pfizer Italia s.r.l); both were dissolved in PBS 
at 50 mg/mL and stored at −20°C.
Determination of maximum tolerated dose (MTD)
MTD of therapeutic agent was defined as the maximum 
dose causing no death and no more than 10% weight loss. 
This was determined by treating wide-type, 8-week-old 
female C57/BL6 J mice (n = 5). Drugs were dissolved in 
400 μL PBS and injected intraperitoneal into these mice. 
Tested doses administered daily for four consecutive days 
were 200, 100, 50, and 25 mg/kg for CTX, and 200, 150, 
100, and 50  mg/kg for Ara-C. Finally, MTD gained was 
100  mg/kg for CTX and 150  mg/kg for Ara-C. These 
doses were then used for primary chemotherapy testing 
in leukemic mice.
Mice and cells
C57/BL6 J mice (CD45.2+, 8-week-old) were used as leu-
kemic hosts. The T-ALL cells were derived from bone 
marrow CD45.1+Lin− hematopoietic cells of B6.SJL 
mice, induced by Notch-1 ICN-GFP over-expression, and 
kindly offered by the State Key Laboratory of Experimen-
tal Hematology Tianjin, China. With no pretreatment, 
each C57/BL6  J mouse was injected with 105 congenic 
T-ALL cells through tail-vein to induce T-ALL devel-
opment in 10  days. Wild type C57/BL6  J mice injected 
with equal volume of PBS were used as normal control. 
Among the normal control mice, those that received 
1-day chemotherapy at MTD doses were defined as the 
drug-only group. T-ALL mice that received chemother-
apy at MTD doses were defined as treated leukemic mice, 
and sub-grouped as follows: the 1-day treated group, 
2-day treated group, 3-day treated group, and 4-day 
treated group. T-ALL mice received 1-day therapy of half 
MTD doses were defined as the lower-dose group. T-ALL 
mice without other interventions were defined as leuke-
mia group.
B6.SJL mice (CD45.1+, 8-week-old) were used as recip-
ients and source of competitive cells in the competitive 
bone marrow transplantation (c-BMT) assays.
All mice were bred and maintained under defined flora 
according to guidelines established and approved by the 
Institutional Animal Committees at the State Key Labo-
ratory of Experimental Hematology Tianjin, China.
Flow cytometry analysis
Murine bone marrow cells were obtained by flushing ili-
ums, femurs and tibias with PBS or PBE. Immuno-phe-
notypes were used as follows: for murine hematopoietic 
stem cell (HSC) was Lin−c-Kit+Sca-1+ (LK+S+), includ-
ing long-term hematopoietic repopulating HSC (LT-HSC; 
CD34−Flk2−LK+S+), short-term repopulating HSC (ST-
HSC; CD34+Flk2−LK+S+), and multi-potent progenitor 
(MPP; CD34+Flk2+LK+S+); for murine hematopoietic 
progenitor cell (HPC) was Lin−c-Kit+Sca-1− (LK+S−), 
sub-divided as granulocyte/macrophage progeni-
tor (GMP; CD34+CD16/32+LK+S−), common mye-
loid progenitor (CMP; CD34+CD16/32−LKS−), 
and megakaryocyte/erythroid progenitor (MEP: 
CD34−CD16/32−LK+S−). Normal hematopoietic and 
leukemic cells were discriminated by CD45.2, GFP, or 
CD45.1 expressions. For detection of HSC/HPC and 
their sub-populations, we used FITC conjugated CD34 
(RAM34, e-Bioscience), APC-cy7 conjugated with a 
mixture of lineage antibodies (anti-CD3 145-2C11, CD4 
GK1.5, CD8 53-6.7, Mac-1 M1/70, B220 RA3-6B2, Gr-1 
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RB6-8C5, Ter-119 TER-119; all were purchased from 
e-Bioscience), Streptavidin APC-cy7 (BD), PE-cy7 con-
jugated Sca-1 (D7, e-Bioscience), APC conjugated c-Kit 
(2B8, e-Bioscience), PE conjugated CD16/32 (93, e-Bio-
science) and Flk2 (A2F10.1, BD), Percp-cy5.5 conjugated 
CD45.2 (104, BD) and PE conjugated CD45.2 (104, e-Bio-
science). All analysis was performed on an LSR Aria II 
flow cytometer (BD Bioscience) and further studied by 
FlowJo 7.6 software (FlowJo LLC, Ashland, OR, USA).
Analysis of apoptosis by flow cytometry
For apoptosis assays, the staining was performed in the 
staining buffer with FITC conjugated Annexin-V and 
7-AAD (5 µL in 100 µL cells for both dyes; BD Pharmi-
gen™ FITC Annexin V Apoptosis Detection Kit) at 37°C 
for 15 min according to the user’s manual and analyzed 
using flow cytometry within an hour after staining was 
completed.
Cell cycle analysis
For cell-cycle analysis, 100  µL pre-stained cells were 
fixed, and then after permeabilization, they were further 
stained with 5 µL PE conjugated Ki-67 (BD) at 37°C for 
30 min, then 5 µg Hoechst 33,342 (10 µg/mL, Life Tech-
nologies) was added into 500  µL cell suspension before 
flow cytometry analysis. Cells were discriminated in G0 
(Hochestlow Ki-67low), G1 (Hochestlow Ki-67high), and 
G2-S-M (incorporation of both Hochest and Ki-67).
In vitro colony‑forming cell (CFC) assay
CD45.2+GFP− BM cells of the leukemic and the 1-day 
treated groups were sorted on the 1st, 2nd, 5th, and 12th 
days post chemotherapy for in vitro colony-forming cell 
assay, respectively. Cells were seeded in methylcellulose 
medium M3434 (Stem Cell Technologies) and plated 
in 24-well plates with a 0.5  mL volume at a density of 
2 × 104/mL; five replicates per well. Cells were cultured 
at 37°C, with 5% CO2 and ≥95% humidity. After 10 days 
of culture, colonies were counted under an inverted 
microscope and recorded in specific lineages.
Competitive bone marrow transplantation assay
CD45.2+ BM cells were sorted from the 1-day treated 
leukemic mice on the 1st, 2nd, 5th, and 12th days post 
therapy for c-BMT assay, respectively. A total number 
of 5 × 105 sorted viable CD45.2+ cells together with an 
equal number of viable CD45.1+ competitive cells (from 
wide-type untreated 8-week-old B6.SJL female mice) 
were co-transplanted into lethally irradiated (9.5  Gy) 
female B6/SJL mice (n =  9/group, 8-week-old) through 
tail-vein injection 6  h after irradiation. After transplan-
tation, tail-vein blood was tested for donor contribution 
and lineage differentiation 1 month later and monthly for 
four consecutive months since. Relative contributions of 
tested (CD45.2+) and competitive cells (CD45.1+) were 
analyzed using FITC conjugated CD45.2 (104, Bio-leg-
end) and Percp-cy5.5 conjugated CD45.1 (A20, BD). Dif-
ferentiation status was analyzed using following lineage 
markers: APC conjugated Mac-1 (M1/70, e-Bioscience) 
for myeloid lineage, PE conjugated CD3 (145-2C11, 
e-Bioscience) for T lineage and PE-cy7 conjugated B220 
(RA3-6B2, e-Bioscience) for B lineage. Analysis was done 
by flow cytometry.
Senescence analysis using flow cytometry
Senescent status of cells was examined according to 
the manufacture’s instruction of the ImaGene Green™ 
C12-FDG lacZ Gene Expression Kit (Molecular Probes, 
Inc.), and further guided by a Nature Protocol suggested 
method [5].
Cell sorting procedures
For HSC (LK+S+ cells) isolation, BM cells were firstly 
enriched for c-Kit expression by immuno-selection with 
CD117 conjugated micro-magnetic beads (Miltenyi 
Biotec) according to the manufacturer’s instructions. 
Enriched cells were then stained with PE-cy7 conju-
gated with a mixture of lineage antibodies (anti-CD3 
145-2C11, Mac-1 M1/70, Gr-1 RB6-8C5, CD4 GK1.5, 
B220 RA3-6B2, CD8 53-6.7, Ter-119 TER119; all were 
purchased from e-Bioscience), PE conjugated Sca-1 (D7, 
e-Bioscience), APC conjugated c-Kit (2B8, e-Bioscience) 
and Percp-cy5.5 conjugated CD45.2 (104, e-Bioscience). 
Normal hematopoietic and leukemic cells were sorted by 
CD45.2 and GFP expression, respectively; and 4′,6-diami-
dino-2-phenylindole (DAPI) was used to exclude dead 
cells during the sorting procedure.
Quantitative reverse transcriptase PCR (qRT‑PCR)
A total number of 2 ×  104 BM CD45.2+LK+S+ cells or 
GFP+ cells were sorted directly into the lysis buffer (Strat-
agene). Total RNA was extracted with the RNA nano-
prep kit according to the manufacturer’s instructions 
(Stratagene). Reverse transcription was achieved using 
oligo-dT and M-MLV reverse transcriptase (Ambion). 
Real-time polymerase chain reaction (PCR) was per-
formed with SYBR green Master Mix (Finnzymes), using 
a Real-time Quantitative PCR 7500 (ABI) machine. 
Parameters were as follows: Holding stage: 95°C, 10 min, 
1 cycle; Cycling stage: 95°C, 15 s, 60°C, 50 s, for 60 cycles; 
Melt curve stage: 95°C, 15 s, 1 cycle, 60°C, 1 min, 1 cycle, 
95°C, 15 s, for 1 cycle. The sequences of all primers used 
in the qRT-PCR assay are listed in the Additional file 1: 
Table S1.
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Statistical analysis
Data are presented as mean ± SEM if not indicated oth-
erwise. Survival status was analyzed using Kaplan–Meier 
analysis. Differences between two groups were analyzed 
using a two-tail unpaired Student t test. For compari-
son of multiple groups, one-way ANOVA was used and 
followed by Dunnett analysis between each of the two 
groups. Differences with a P value ≤0.05 were considered 
statistically significant.
Results
Development of a system for evaluation of chemotherapy 
on leukemia mice
In order to get insight into the effects of chemotherapy 
on primitive hematopoietic cells and leukemic cells, we 
established a leukemia-therapy model as illustrated in 
Figure  1a. Histopathological examination of dying mice 
revealed leukemic infiltration in spleen, bone marrow, 
and liver (Figure 1b). Flow cytometric analysis of leuke-
mic cells confirmed their immunophenotype as CD45.1
+GFP+CD3+CD4+CD8+, indicating T-ALL (Figure  1c). 
Whole blood cell counts in peripheral blood of these 
mice showed a gradual decrease of hemoglobin and 
platelet together with leukocytosis (Figure 1d), as well as 
an increase of lymphocytes (Figure 1e). Leukemic burden 
in bone marrow and found it gradually increased (Fig-
ure  1f ). The leukemic mice had much shorter life-span 
(median survival time: 29  days; control: no mice died 
within the 40 inspecting days; P = 0.0001; Figure 1g).
With different treat modalities, we set up course-
dependent treating models leading to different kinetics 
of leukemic cells and normal hematopoietic cells (Addi-
tional file  2: Figure S1). In this study, we use one-dose 
treatment model which facilitates the study.
Treatment was administrated when leukemic burden 
reached 1–5% of mononuclear cells in peripheral blood 
(Figure 1a). The chemotherapy combination included two 
drugs, CTX (100  mg/kg) and Ara-C (150  mg/kg) with 
one dose. The treated leukemic mice lived much longer 
than those without treatment (median survival days: 
39.5 vs. 29  days, P  =  0.002; Figure  1h). Leukemic cells 
in peripheral blood and bone marrow decreased rightly 
post treatment, and reached plateau during day 2–5, then 
recovered at day 7 (Figure 1i–j). The leukemia cells infil-
trated the bone marrow and spleen. (Additional file  3: 
Figure S2). Of note, we observed a period (the day 2 to 
the day 5 post therapy) when leukemic cells could hardly 
be detected with a nearly uncompromised platelet count 
(Figure 1i–k). We defined this status as complete remis-
sion (CR). On day 7, leukemia cells (GFP+) relapsed. 
Thus, we successfully established a CR-to-relapse T cell 
leukemia model in non-irradiated mice with combined 
chemotherapy.
Primitive hematopoietic cells showed an earlier 
regeneration than leukemic cells
An important characteristic of HSC is its self-renewal 
ability, which is key for its quantity and quality main-
tenance [6]. We quantitatively analyzed bone marrow 
primitive hematopoietic cells in the one-dose treated leu-
kemia model. Both CD45.2+L−K+S+, CD45.2+L−K+S− 
hematopoietic cells and their sub-populations were 
analyzed by flow cytometry. CD45.2+L−K+S+ hemat-
opoietic cells decreased on day 1 post therapy (mean 
number: 1.523  ±  271.4  ×  104), and regenerated rap-
idly from day 2 (mean number: 4.298  ±  2.866  ×  104). 
And the cell number reached the peak on the 5th 
day, and gradually decreased since (mean number: 
15.217 ±  2.243 ×  104) on the 5th day; 14.960 ±  0.7069 
on the 7th day; 1.825 ±  0.4581 ×  104 on the 12th day). 
CD45.2+L−K+S− hematopoietic cells showed a similar 
trend. However, leukemic cells began to regenerate since 
the 5th day and continued proliferating thereafter (Fig-
ure 2c, d, Additional file 4: Figure S3A, B).
We then analyzed sub-populations of CD45.2+L−K+S− 
and CD45.2+L−K+S− hematopoietic cells in bone 
marrow. We found that since the recovery phase, 
CD45.2+L−K+S− hematopoietic cells showed a granulo-
cyte monocyte progenitor (GMP)-biased manner when 
compared with control (on the 2nd day 61.80 ± 3.25%; on 
the 3rd day 67.18 ± 1.93%; on the 5th day 76.50 ± 3.46%; 
on the 7th day 76.75  ±  1.63%; on the 12th day 
64.00  ±  2.84%; all P values <0.05 when compared with 
control; Figure  2e). We had similar results for colony-
forming cell assays (Additional file 5: Figure S4B–E). For 
CD45.2+L−K+S− hematopoietic cells, on the 3rd day 
CD45.2+LK+S+ hematopoietic cells showed a decreased 
frequency of phenotypically defined LT-HSC compared 
to control (4.73  ±  0.61% vs. normal 12.44  ±  0.69%, 
P < 0.0001; Figure 2f ). This might be a compensating loss 
of mature cells caused by leukemia and chemotherapy; 
since the 5th day post therapy, frequencies restored back 
to a nearly normal level.
We then compared the one-dose treated leukemic mice 
with the untreated leukemia group in the late leukemia 
relapsing stage (on the 12th day). Although there was no 
significant difference in absolute numbers (296.2 ± 87.88 
vs. 174.0 ± 53.93, P = 0.252; Figure 2j), CD45.2+L−K+S− 
hematopoietic cells showed a significant lower percent-
age in treated group (0.01 ± 0.001% vs. 0.024 ± 0.003%, 
P  =  0.008; Figure  2n), suggesting that chemotherapy 
leading to a decreased frequency of LT-HSC.
We also tested related parameters in the lower-dose, 
the four-dose treated and the treatment only groups. 
In the lower-dose treated group, we observed a similar 
trend of primitive hematopoietic cells and leukemic cells, 
although to a less extent (Additional file 6: Figure S5). In 
Page 5 of 12Jiang et al. J Transl Med  (2015) 13:234 
the four-dose treatment group, we found that leukemic 
burden in peripheral blood was continuously undetecta-
ble within 90 days post therapy, and primitive hematopoi-
etic cells in bone marrow could recover back to normal 
status post therapy (Additional files 2, 7: Figures S1, S6). 
Moreover, CD45.2+LK+S− cells showed a same shift 
towards GMP differentiation comparable to the one-dose 
treated leukemic group during the early recovery phase 
(Additional file 7: Figure S6). We also tested these in the 
treatment only group. Data showed that the frequencies 
of both L−K+S+ and L−K+S− cells recovered to the nor-
mal in the end (Additional file 8: Figure S7A–C).
Figure 1 Experimental design and a CR-to-relapse treated leukemic model established in non-irradiated T-ALL mice. a Schematic representation of 
experimental strategy. Eight-week-old C57/BL6 J mice (CD45.2+), each injected with 105 congenic T-ALL cells (CD45.1+), are used to develop T-ALL. 
When leukemic cells reach 1–5% of the mononuclear cell (MNC) in peripheral blood (PB) of these mice, chemotherapy (Ara-C and CTX) is given, 
and both leukemic cells and normal hematopoiesis are examined thereafter. b Leukemic infiltration in spleen, bone marrow and liver of the dying 
T-ALL mice in the late disease stage. Mice injected with T-ALL cells were sacrificed on the 21st day post injection for histopathological evaluation. 
Tissues were collected and fixed with 10% formalin overnight, stained with hematoxylin-eosin (H&E) and examined by an inverted microscopy. 
c Expression of T-ALL cell markers on flow cytometry for the leukemic cells as GFP+CD45.1+CD3+CD4+CD8+. d–e Peripheral blood cell counts 
of T-ALL mice showed a gradual appearance of lymphocytic leukocytosis and decreased hemoglobin and platelets (n = 3–4). Peripheral blood 
samples were tested by an automatic whole-blood analyzer (XT-2000T; SysmHGBex). f Leukemic burden in BM of T-ALL mice increased daily, and 
reached nearly 10% of MNC on the 12th day post injection (n = 4). g T-ALL mice showed a much shorter life-span compared to the normal control 
(median survival days post T-ALL cells injection: 29; n = 19; p = 0.0001). h–k When leukemic burden of the T-ALL mice reached about 1–5% in PB, 
mice received 1-day therapy composed of Ara-C (150 mg/kg) and CTX (100 mg/kg). h The treated leukemic mice (1-day treated leukemic group) 
showed prolonged survival time compared to the untreated leukemic group (median survival days post T-ALL cells injection: 39.5 vs. 29; n = 10; 
p = 0.002). i Leukemic burden in PB of the treated leukemic mice at different time points post therapy (n = 6–8). j Leukemic burden in BM of the 
treated leukemic mice at different time points post therapy (n = 3–4). Leukemic burden in PB and BM both decreased right after treatment, and 
regenerated since the 5th day post therapy. It was nearly undetectable on the 2nd to the 5th day post therapy. k Platelet count in PB of the treated 
leukemic mice post therapy (n = 6–9). It showed no significant difference when compared with the PBS injected control mice, though there was a 
decrease tread on the 12th day post therapy when leukemia relapsed. All data were presented as mean ± SEM.
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In the present model, primitive hematopoietic cells and 
leukemic cells showed different kinetics together with a 
GMP-bias of the hematopoietic progenitors and an addi-
tional consumption of phenotypically defined LT-HSC 
possibly due to chemotherapy.
Transient and intensive proliferation of bone marrow 
L−K+S+ hematopoietic cells
Cell proliferation and apoptosis are two opposite factors 
influencing cell numbers. Next, we further investigated 
these parameters in L−K+S− and L−K+S+ hematopoi-
etic cells. We chose the 1st, 2nd, 5th, and 12th days post 
therapy as further testing time-points in the one-dose 
treated leukemic group and results were compared with 
the control group. Nine hours after therapy (presented 
as 0.4  day) was also tested to exclude the possibility of 
missing early acting phase. Compared with the control, 
although with no statistical significance, treated leuke-
mic mice showed increased percentages of apoptosis of 
CD45.2+L−K+S− cells early after therapy, while no differ-
ences thereafter (day 0: 7.85 ± 1.78%; 9 h: 5.78 ± 1.00%; 
day 1: 17.70  ±  1.39%; day 2: 11.64  ±  1.65%; day 5: 
5.87 ± 2.23%; day 12: 7.67 ± 3.39; all P values >0.05 when 
compared to normal except day 1, Figure 3). Data showed 
that apoptosis was involved in the decrease of primitive 
hematopoietic cells post therapy, especially in the early 
phase.
Then we examined cell cycle status of both primitive 
hematopoietic cells and leukemic cells in bone mar-
row of the 1-day treated leukemic mice. Figure  4a–c 
showed the representative flow cytometry plots for the 
CD45.2+LK+S−, CD45.2+LK+S+ hematopoietic cells, 
and CD45.1+ leukemic cells, while statistical analyses are 
presented in Figure 4d–i. CD45.2+LK+S− hematopoietic 
cells exhibited a relatively stable status, a much larger part 
of these cells kept in G2-S-M phase compared to normal 
control, indicating a much more active proliferation sta-
tus of these cells post therapy (Figure  4d–f). While for 
CD45.2+LK+S+ hematopoietic cells, they went through 
complex changes of cell cycle. A large proportion of these 
cells rapidly left G0 phase and entered G2-S-M prolif-
erating period post therapy (mean percentage of cells 
Figure 2 Primitive hematopoietic cells showed an earlier regeneration than leukemic cells post therapy. a Representative flow cytometry plots 
of leukemic cells in the BM of the 1-day treated leukemic mice on the therapeutic day (d0), and on the 1st, 2nd, 5th, and 12th day post therapy. b 
Representative flow cytometry plots of CD45.2+LK+S+ and CD45.2+LK+S− cells in the BM of normal control (shown as N) and the 1-day treated 
leukemic mice post therapy. Cells were gated in CD45.2+Lin− populations. c Frequencies of leukemic cells in whole MNCs and CD45.2+LK+S− and 
CD45.2+LK+S+ cells in CD45.2+ hematopoietic cell fractions in the BM of the 1-day treated leukemic mice on the therapeutic day (d0) and follow-
ing days (n = 3–4). d Total numbers of leukemic cells, CD45.2+LK+S− and CD45.2+LK+S+ cells in the BM (double hindlimbs) of the 1-day treated 
leukemic mice on different time (n = 3–4). e Frequencies of CMP, GMP, and MEP in CD45.2+LK+S− cells in the BM of normal control and the 1-day 
treated leukemic mice on different time (n = 3–8). f Frequencies of LT-HSC, ST-HSC, and MPP in CD45.2+LK+S+ cells in the BM of normal control and 
the 1-day treated leukemic mice on different time (n = 3–9). g–j Total numbers of LT-HSC, ST-HSC, MPP, and CD45.2+LK+S+ cells of the leukemia-
only control and the 1-day treated leukemic mice in BM (double hindlimbs) on different days (n = 3–6). k–n Frequencies of LT-HSC, ST-HSC, MPP 
and CD45.2+LK+S+ cells in CD45.2+ hematopoietic cell fractions in the BM of the leukemia-only control and the 1-day treated leukemic mice on 
different days (n = 3–6). All data were presented as mean ± SEM. Statistical significance determined as: *p < 0.05; **p < 0.01; ***p < 0.001.
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in G2-S-M phase %: on the therapeutic day 6.11 ± 0.63; 
on the 1st day post therapy 9.48 ± 1.06; on the 2nd day 
22.55  ±  0.64; Figure  4f ). As expected, when leukemia 
relapsed, they went back into arrest (mean percentage 
of cells in G2-S-M phase on the 5th day: 5.79 ±  0.86%; 
Figure  4f ). However, in the late leukemia relapsing 
stage, we found that there was a large percentage of 
CD45.2+LK+S+ hematopoietic cells in G2-S-M phase 
compared with normal control (mean percentage of cells 
in G2-S-M phase %: on the 12th day 15.78 ± 2.11 vs. nor-
mal 10.37 ± 0.98; p = 0.026; Figure 4f ). However, in the 
drug-only group, cell cycle status of these cells returned 
to normal in the end though they also experienced com-
plex changes during the hematopoietic recovery phase 
(Additional file  8: Figure S7D–F). When we focused on 
leukemic cells in bone marrow of the leukemia-therapy 
mice, we found they entered proliferation later than 
CD45.2+LK+S+ hematopoietic cells. They showed up 
again since the 5th day, and entered into a persistent pro-
liferation period since the 7th day post therapy. Although 
frequencies of leukemic cells in G0 phase decreased, 
G2-S-M showed a relatively stable status except for the 
1st day post therapy. Interestingly, a large proportion of 
leukemic cells was in G2-S-M phase, together with sig-
nificantly decreased G1 proportion on the 1st day post 
therapy compared to the therapeutic day (G2-S-M phase 
frequency %: 63.54 ± 2.16 vs. 21.83 ± 1.13, p < 0.0001; G1 
phase frequency: 15.21 ± 2.49 vs. 55.5 ± 0.74, p < 0.0001; 
G0 phase frequency: 18.35  ±  1.45 vs. 21.18  ±  1.55, 
p = 0.256; Figure 4g–i). These results were confirmed in 
the lower-dose treated group (Additional file  6: Figure 
S5). Gene analysis found coincident expression changes 
of cell cycle related genes, and CDK4, CDK6, and Cyclin 
D1 were the main different ones, indicating their possi-
ble role in mediating different changes of leukemic cells 
and CD45.2+LK+S+ hematopoietic cells post therapy 
(Figure 4j–n).
Data presented above indicate that cell proliferation 
and apoptosis were both presented in a dynamic manner 
post therapy. Cell cycling was the main factor responsi-
ble for different changes of primitive hematopoietic cells 
and leukemic cells post therapy; while apoptosis mainly 
Figure 3 Apoptosis has little effect on changes of LK+S−/LK+S+ hematopoietic cells since the recovery phase. a Gating strategy for apoptosis 
using 7-AAD and Annexin-V staining. The cellular uptake of these dyes discriminated cells in Alive (7-AADlow Annexin-Vlow), Necrosis (Annexin-Vlow 
7-AADhigh) and Apoptosis (Annexin-Vhigh 7-AADlow). b–e Percentages of viable CD45.2+LK+S− cells (b), apoptotic CD45.2+LK+S− cells (c), viable 
CD45.2+LK+S+ cells (d), apoptotic CD45.2+LK+S+ cells (e) in the BM of normal control (shown as N) and the 1-day treated leukemic mice on differ-
ent days (n = 4–5).
Page 8 of 12Jiang et al. J Transl Med  (2015) 13:234 
affected the early phase post therapy, and was apparently 
ignorable since recovery of both CD45.2+LK+S+ and 
CD45.2+LK+S− hematopoietic cells.
Gradually diminished regenerative capacity of primitive 
hematopoietic cells
Another important feature of HSCs is their ability to 
reconstitute long-term multi-lineage hematopoiesis [6]. 
We therefore further examined the regeneration capabil-
ity with competitive bone marrow transplantation assays 
using HSCs harvesting on the 1st, 2nd, 5th, and 12th day 
post therapy. CD45.2+ bone marrow hematopoietic cells 
were sorted out on the indicated days and co-transplanted 
with equal number of CD45.1+ competitive cells into 
lethally irradiated mice (Figure 5a). The donor contribu-
tion of the hematopoietic cells sorted at the four check-
ing-points post therapy gradually decreased, indicating 
a gradual loss of repopulating ability of bone marrow 
hematopoietic cells in our model. To exclude influences of 
the different frequencies of primitive hematopoietic cells 
in whole bone marrow of the four independent tested 
cell populations, we further calculated the donor contri-
butions of whole bone marrow hematopoietic cells over 
the corresponding frequencies of bone marrow primi-
tive hematopoietic cells (herein referred to HSC and LT-
HSC). We also observed a gradual loss of repopulating 
capabilities, providing further evidence of dysfunction of 
primitive hematopoietic cells in reconstitution. Lineage 
differentiation showed no difference in the first 2 months, 
however, in the following 2 months, myeloid differentia-
tion seemed to be impaired (Figure 5c). These results sug-
gested that normal hematopoiesis were impaired in the 
one-dose treated leukemic hosts as shown by diminished 
repopulating ability and impaired myeloid differentiation.
Figure 4 Primitive hematopoietic cells showed a dramatic cell-cycle activation after therapy ahead of leukemic cells. Cell cycle status of primitive 
hematopoietic cells and leukemic cells in the BM post therapy was analyzed by Ki-67 and Hoechst staining on flow cytometry. CD45.2+LK+S+ cells 
and leukemic cells post therapy were sorted and the expression patterns of cell-cycle related genes in these cells were examined. CD45.2+LK+S+ 
cells from normal control and leukemic cells sorted from leukemia-only mice were used as control for either cell type, respectively. a Representa-
tive flow cytometry plots of cell-cycle of CD45.2+LK+S− cells in the BM of normal control and the 1-day treated leukemic mice on different days as 
indicated. b Representative flow cytometry plots of cell-cycle of CD45.2+LK+S+ cells in the BM of normal control and the 1-day treated leukemic 
mice on different days. c Representative flow cytometry plots of cell-cycle of leukemic cells in the BM of the 1-day treated leukemic mice on dif-
ferent days. d–f Cell-cycle status of CD45.2+LK+S− and CD45.2+LK+S+ cells in the BM of normal control and the 1-day treated leukemic mice on 
different days (n = 3–7). g–i Cell-cycle status of leukemic cells in the BM of the 1-day treated leukemic mice on different days (n = 4–8). j–k Gene 
expression patterns of CD45.2+LK+S+ cells in the BM of normal control and the 1-day treated leukemic mice on the 3rd and 5th day post therapy. 
l–n Gene expression patterns of leukemic cells in the BM of the leukemia-only and the 1-day treated leukemic mice on the 1st, 5th, and 12th day 
post therapy. All data were presented as mean ± SEM. Statistical significance determined as: *p < 0.05; **p < 0.01; ***p < 0.001.
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Senescence is confirmed in L−K+S+ hematopoietic cells
Cellular senescence is usually a result of extensive rep-
lication, and mainly occurs prematurely after cells are 
exposed to oncogenic, oxidative, or genotoxic stress 
[7–9]. Reports have discussed the role of senescence in 
mediating impairment of HSC function. In the hemat-
opoietic system, studies mainly focused on irradiation 
[10, 11]. Since HSCs went through accelerated cycling 
together with decreased regenerative function and atypi-
cal differentiation pattern, a high level of cell senescence 
is therefore expected in these HSCs. Senescent cells 
express increased levels of biomarkers, such as SA-β gal 
and P16 [12, 13]. Here we employed a enzymatic method 
suggested by Nature Protocols to detect SA-β gal activity. 
The method involves the alkalinization of lysosomes, fol-
lowed by the use of 5-dodecanoylaminofluorescein di-β-
d-galactopyranoside (C12FDG), a fluorogenic substrate 
of SA-β gal which becomes fluorescent after cleaved by 
the enzyme and can be detected by flow-cytometry [5]. 
Senescent status of CD45.2+L−K+S+ hematopoietic cells 
in our 1-day treated leukemic model on the 3rd and 5th 
day post therapy were measured, and compared to the 
normal control. CD45.2+L−K+S+ hematopoietic cells of 
the 1-day treated leukemic mice on the 3rd and 5th days 
post therapy showed higher mean fluorescence intensity 
(MFI) of C12-FDG (normal vs. day 3: 124.6 ±  20.27 vs. 
539.7 ± 126, p = 0.0069; normal vs. day 5: 124.6 ± 20.27 
vs. 296.6 ± 51.94, p = 0.0259; Figure 5e), indicated higher 
levels of senescence.
We then analyzed gene expressions of p16, p21, and 
p53, three key genes involved in cellular senescence 
[14–16]. Data showed higher expression of P16 and P21 
in CD45.2+LK+S+ hematopoietic cells on the 3rd and 5th 
days post therapy, further confirming the result of senes-
cence (Figure 5f–g).
Moreover, we also observed down-regulated expres-
sions of Egr1 and FOS on these 2 days (Figure 5f, g). Egr1 
is a gene affecting hematopoiesis. Although loss of Egr1 
does not impair regenerative ability in primary recipient 
mice, Egr1−/− HSCs exhibit premature loss of function 
during serial transplantation, suggesting its protective 
function of HSC in the case of replicative stress [17, 18]. 
FOS is also found to be involved in stem cell mainte-
nance, stem cell niche interactions and oxidative stress 
Figure 5 Gradual loss of regenerative capacity of primitive hematopoietic cells involved in the treated leukemic model, caused by excessive 
proliferation related senescence. a Competitive bone marrow transplantation assays were used to examine the regenerative capacity of hemat-
opoietic cells in vivo. CD45.1+ bone marrow cells from wild-type B6.SJL female mice (5 × 105) and CD45.2+ bone marrow cells (5 × 105) sorted 
from the 1-day treated leukemic mice on different days post therapy were co-transplanted into each B6.SJL mice (CD45.1+) which have undergone 
lethal irradiation (9.5 Gy). Donor contribution and lineage differentiation status were examined 1 month later at a frequency of once per month for 
four consecutive months. b Donor contribution on the fourth month post transplantation was examined and deeply analyzed combined with the 
frequencies of HSC (CD45.2+LK+S+ cells) and LT-HSC (CD45.2+LK+S+CD34−Flk2− cells) in BM CD45.2+ hematopoietic cell fractions of the 1-day 
treated leukemic mice on the indicated days tested by flow cytometry (n = 3–9). c Lineage differentiation status of the 4 months post transplanta-
tion (n = 3–9). d, e Higher levels of senescence confirmed in primitive hematopoietic cells post therapy compared to normal control. Senescence 
status of CD45.2+LK+S+ cells in the BM of normal control and the 1-day treated leukemic mice were tested on the 3rd and 5th day post therapy 
by C12-FDG staining. The representative flow cytometry plots are shown in d, while the statistic results (n = 7–12) are shown in e. f, g Expression 
patterns of genes regulating HSC function in primitive hematopoietic cells changed post therapy. CD45.2+LK+S+ cells of normal control and the 
1-day treated leukemic mice on the 3rd and 5th day post therapy were sorted out and used for analysis of gene expression patterns, including p16, 
p21, p53, EGR1 and FOS. All data were presented as mean ± SEM. Statistical significance determined as: *p < 0.05; **p < 0.01; ***p < 0.001; ns not 
significant.
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response [19, 20]. These results suggest that excessive 
proliferation induced the functional impairment.
Discussion
Leukemia patients usually die of refractory disease, 
relapse and treatment related mortality, so studies focus-
ing on these contexts will be beneficial. Our group in 
2009 reported kinetics of primitive hematopoietic cells 
in an irradiated T-ALL mouse model [1]. In that model, 
the number of primitive hematopoietic cells decreased 
but the cell function was reserved, which may provide an 
explanation on how autologous stem cell transplantation 
works. In the present study, we showed primitive hemat-
opoietic cells went through a highly proliferating phase 
after therapy and exhausted in the end, and leukemic 
cells kept on growing at a much later starting time point 
(on the 5th day after therapy). Our data showed that 
primitive hematopoietic cells and leukemic cells showed 
different proliferation pattern in the leukemia model 
under chemotherapy stress. To our knowledge, this is 
the first time to experimentally demonstrate the earlier 
regeneration of primitive hematopoietic cells than leuke-
mic cell after chemotherapy. Further analysis of cell cycle 
and survival status showed cell cycle was involved, which 
might provide potential therapeutic targets for leukemia 
through cell cycle regulation.
In the irradiated T-ALL mouse model [1], quantity of 
primitive hematopoietic cells was decreased; however 
when transplanted into normal hosts, they could success-
fully reconstitute hematopoiesis comparable to the nor-
mal control, indicating that these primitive hematopoietic 
cells preserved their functionalities in the leukemic con-
text. This suggests that alterations took place in micro-
environment rather than in primitive hematopoietic 
cells themselves. In the present study, we found primitive 
hematopoietic primitive cells altered both in quantity and 
in quality. They showed compromised repopulating capa-
bility in the competitive bone marrow transplantation 
assay. In clinical practice, doctors might meet some diffi-
culties in collecting enough primitive hematopoietic cells 
for autologous stem cell transplantation from patients 
of multiple myeloma, lymphoma, and leukemia, espe-
cially for those who had received high doses or cycles of 
chemotherapy or therapy including some special agents 
[21, 22]. As recently reported, primitive hematopoietic 
cells showed functional injury due to excessive-prolifer-
ation and direct toxicity in aged hosts and hosts suffering 
from chronic infection or acute serious infection [23–27]. 
Similar mechanism may be applied in our 1-day treated 
leukemic model. Moreover, another study found loss of 
quiescence and impaired function of CD34+CD38low cells 
1  year following autologous stem cell transplantation. 
They showed the diminished regenerative capacity was 
possibly due to a loss of quiescence and a reduced toler-
ance to oxidative stress [20]. Our data may offer insights 
on the functional impairment of patients who received 
autologous stem cell transplantation, as all of them would 
had chemotherapy prior to the transplantation. Further 
studies are probably needed to re-evaluate the potential 
toxicity of traditional chemotherapy to primitive hemat-
opoietic cells in future practice.
In the present study, we had some rather interesting 
findings worth further investigation. The first one was 
the myeloid-bias (GMP-bias) of L−KS− hematopoietic 
cells observed in the recovery phase, similar to those 
observed in aged hosts and many other pathological or 
physiological conditions [23, 24, 27]. Under most of 
these conditions, primitive hematopoietic cells displayed 
decreased regenerative ability. Thus, myeloid-bias may 
be a common phenomenon accompanied with impaired 
hematopoiesis, and myeloid lineage may have priority 
in hematopoietic differentiation under stress. Secondly, 
we found a large part of leukemic cells in G2-S-M phase 
1 day post therapy. One report showed that DNA dam-
age of quiescent HSC accumulating during aging was 
repaired by entering cycling, and was important for their 
self-maintenance [28]. Leukemic cells may use the same 
mechanism to recovery from chemotherapeutic attack.
In summary, our study demonstrates different kinet-
ics of leukemic cells and primitive hematopoietic cells 
via different cell cycling following chemotherapy. These 
findings may help us to develop more effective therapeu-
tic methods for leukemia through targeting cell cycling. 
Our data also provide important new insights into the 
mechanism by which chemotherapy causes impaired 
hematopoiesis via induction of premature senescence 
in leukemic patients. A better understanding of these 
mechanisms will allow us to develop new interventions 
to circumvent chemotherapy-induced toxicity to BM 
via targeted inhibition of chemotherapy-induced HSC 
senescence, and this might further improve the chemo-
therapeutic tolerance, especially for those relapsing or 
refractory patients. This will undoubtedly benefit leuke-
mic patients undergoing chemotherapy, especially those 
intending for autologous stem cell transplantation.
Conclusion
In leukemic host, primitive hematopoietic cells in bone 
marrow enter proliferation earlier than leukemic cells 
after chemotherapy, at the cost of regenerative capac-
ity possibly impaired by senescence due to accelerated 
cycling. These findings provide insights on the mecha-
nisms of leukemic relapse, as well the potential toxicity of 
chemotherapy to primitive hematopoietic cells.
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Additional file 7: Kinetics of HSPCs and leukemic cells involved in 
the four-day treated leukemic group. When leukemic cells reached 
1-5% in PB, mice received four consecutive days of treatment, composed 
of 150 mg/kg Ara-C plus 100 mg/kg CTX daily. Then changes of leukemic 
cells and primitive hematopoietic cell fractions were tested. (A) Leukemic 
burden in the BM was continuously undetectable within 40 days post 
therapy (n = 5). (B) Bone marrow cellularity showed a gradual recovery 
post therapy (n = 5). (C) Frequencies of LK+S+ cells, LT-HSC, MPP and ST-
HSC in CD45.2+ hematopoietic cell fractions in the BM of normal control 
and the four-day treated leukemic mice post therapy (n = 3-5). (D) Total 
numbers of hematopoietic LK+S+ cells, LT-HSC, MPP and ST-HSC in the BM 
(double hindlimbs) of normal control and the four-day treated leukemic 
mice on different days post therapy (n = 3-5). (E) Frequencies of LKS− 
cells, GMP, MEP and CMP in CD45.2+ hematopoietic cell fractions in the 
BM of normal control and the four-day treated leukemic mice on different 
days post therapy (n = 3-5). (F) Total numbers of hematopoietic LK+S− 
cells, GMP, MEP and CMP in the BM (double hindlimbs) of normal control 
and the four-day treated leukemic mice on different days post therapy (n 
= 3-5). All data were presented as mean±SEM. Statistical significance as: * 
p<0.05; ** p<0.01; *** p<0.001.
Additional file 8: Kinetics of HSPCs involved in the drug-only 
group. Normal C57/BL6J mice were given one-day therapy, composed of 
150 mg/kg Ara-C plus 100mg/kg CTX. Then changes of primitive hemat-
opoietic cell fractions were tested. (A) Frequencies of CD45.2+LK+S+ 
and CD45.2+LK+S− cells in the BM CD45.2+ hematopoietic cell fractions 
of normal control and the drug-only group mice on different days post 
therapy (n = 3-5). (B) Frequencies of LT-HSC, ST-HSC and MPP in the BM 
CD45.2+LK+S+ hematopoietic cell fractions of normal control and the 
drug-only group mice on different days post therapy (n = 3-5). (C) Fre-
quencies of CMP, GMP and MEP in the BM CD45.2+LK+S− hematopoietic 
cell fractions of normal control and the drug-only group mice on different 
days post therapy (n = 3-5). (D) Frequencies of BM CD45.2+LK+S+ and 
CD45.2+LK+S− cells in G0 phase of normal control and the drug-only 
group mice on different days post therapy (n = 3-5). (E) Frequencies of 
BM CD45.2+LK+S+ and CD45.2+LK+S− cells in G1 phase of normal control 
and the drug-only group mice on different days post therapy (n = 3-5). 
(F) Frequencies of BM CD45.2+LK+S+ and CD45.2+LK+S− cells in G2-S-M 
phase of normal control and the drug-only group mice on different days 
post therapy (n = 3-5). All data were presented as mean ± SEM. Statistical 
significance as: * p<0.05; ** p<0.01; *** p<0.001.
Additional files
Additional file 1: Primer sequences. Sequences of all the primers 
used in qRT-PCR.
Additional file 2: Course-dependent chemotherapy response of 
the T-ALL mice. When leukemic cells reached 1-5% in PB, mice received 
chemotherapy composed of CTX (100 mg/kg) and Ara-C (150 mg/kg) for 
a consecutive 1, 2, 3 and 4 days, respectively. (A) Median survival days post 
leukemic cell injection were 29, 39.5, 45 and 71.5 for the leukemia-only, 
one-day treated, two-day treated and three-day treated group, respec-
tively (n = 6-10). For the four-day treated group, no mice died within the 
inspecting 90 days (n = 6). (B) Leukemic burden in PB of the four differ-
ently treating groups (n = 6). Data showed that longer the therapeutic 
course, longer the relapse-free period. The day on which leukemic cells 
showed up again in PB for the one-day, two-day and three-day treated 
groups were the 8th, 11th and 17th day post therapy, respectively. While 
for the four-day treated group, no appearance of relapse was detected 
within the inspecting 90 days. (C) White blood cell count in PB of the four 
differently treating groups (n = 6). Data showed that longer the therapeu-
tic course, heavier the depression of white blood cells post therapy. (D) 
Platelet count in PB of the four differently treating groups (n = 6). Data 
showed that longer the therapeutic course, longer the suppression period 
of platelet in PB post therapy. All data were presented as mean±SEM. 
Statistical significance as: * p<0.05; ** p<0.01; *** p<0.001.
Additional file 3: Histopathology of the one-day treated leukemic 
mice. Mice of the one-day treated leukemic group were sacrificed at 
different time points post therapy for histopathological analysis. Tissues 
were gained right after sacrifice, fixed in 10% formalin overnight, stained 
by hematoxylin-eosin (H&E) and examined by an inverted microscopy. (A) 
Status of leukemic infiltration and normal hematopoiesis in spleen post 
chemotherapy. (B) Status of leukemic infiltration and normal hematopoie-
sis in bone marrow post therapy.
Additional file 4: Kinetics of HSPCs and leukemic cells involved in 
the one-day treated leukemic group. (A) Frequencies of leukemic cells 
in whole MNCs and CD45.2+LK+S+ and CD45.2+LK+S− cells in CD45.2+ 
hematopoietic cell fractions in the BM of the one-day treated leukemic 
mice (n = 3-4). (B) Total numbers of leukemic cells, CD45.2+LK+S+ and 
CD45.2+LK+S− cells in BM (double hindlimbs) of the one-day treated leu-
kemic mice (n = 3-4). (C) Statistic analysis of sub-populations of CD45.2+ 
hematopoietic cell fractions in the one-day treated leukemic mice (n = 
3-4). All data were presented as mean ± SEM.
Additional file 5: Results of the in vitro colony-forming cell assays 
in the one-day treated leukemic mice. CD45.2+ hematopoietic cells 
in the BM of the one-day treated leukemic mice were sorted for in vitro 
colony-forming cell assays on different days post therapy. CD45.2+ hemat-
opoietic cells in the BM of leukemia-only mice were used as control. (A–D) 
Results of the CFC assays (n = 4-5). Data showed similar changing trend of 
hematopoietic progenitors and the same granulocyte shift in the prolifera-
tion phase coincident with flow cytometric data. All data were presented 
as mean±SEM. Statistical significance as: * p<0.05; ** p<0.01; *** p<0.001.
Additional file 6: Kinetics of HSPCs and leukemic cells involved in 
the lower-dose treated leukemic mice. When leukemic cells reached 
1-5% in PB, mice received one-day of lower-dose therapy, composed of 75 
mg/kg Ara-C plus 50mg/kg CTX. Then changes of leukemic cells and primi-
tive hematopoietic cell fractions were tested. (A) Frequencies of leukemic 
cells in whole MNCs and CD45.2+LK+S−, CD45.2+LKS+ cells in CD45.2+ 
hematopoietic cell fractions in the BM of the lower-dose treated leukemic 
mice (n = 3-4). (B) Frequencies of LKS− cells, CMP, GMP and MEP in CD45.2+ 
hematopoietic cell fractions in the BM of normal control and the lower-
dose treated leukemic mice on the 1st, 2nd and 3rd day post therapy (n = 
5-9). (C) Frequencies of LK+S+ cells, LT-HSC, MPP and ST-HSC in CD45.2+ 
hematopoietic cell fractions in the BM of normal control and the lower-dose 
treated leukemic mice on different days post therapy (n = 5-9). (D–F) Cell-
cycle status of leukemic cells, CD45.2+LK+S− and CD45.2+LK+S+ cells in the 
BM of the lower-dose treated leukemic mice on the therapeutic day (d0), 
and on the six consecutive days since (n = 3-5). All data were presented as 
mean±SEM. Statistical significance as: * p<0.05; ** p<0.01; *** p<0.001.
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